The Right Fit, Not Just the Right Drug: What 2026's PETRUSHKA Trial Means for Your Depression Care
When depression makes everyday life feel heavier, finding care that fits can matter as much as finding care that is clinically sound. A treatment plan may be evidence-based, but it also needs to be realistic, tolerable, and aligned with the person receiving it.
That is the central lesson I take from the new PETRUSHKA trial, published by Cipriani and colleagues in JAMA and discussed by The Mental Elf on September 30, 2026. The study tested a digital decision-support tool designed to help clinicians and patients choose an antidepressant based not only on clinical information, but also on the patient’s own priorities, especially which side effects they most want to avoid.
The headline may sound like artificial intelligence or machine learning. For me, the more important headline is simpler:
People deserve a meaningful voice in decisions about their mental health care.
What PETRUSHKA Did Differently
Antidepressant decisions are often made using a combination of clinical experience, general treatment guidelines, past history, and trial and error. Those factors remain important. But two people with similar depression symptoms may have very different needs and concerns.
One person may be especially concerned about sedation. Another may worry about sexual side effects, weight changes, nausea, or feeling emotionally disconnected. Someone else may prioritize avoiding a medication that could interfere with work, parenting, driving, or sleep.
PETRUSHKA was designed to bring those preferences directly into the conversation. The digital tool combines:
Machine-learning prediction models
Information about the patient’s symptoms, history, and circumstances
Evidence from electronic health records and clinical trials
The patient’s stated preferences about treatment benefits and side effects
The tool then provides a ranked list of antidepressant options that may be a better fit for that particular person. It does not replace the prescribing clinician or make an automatic decision. Instead, it supports a shared conversation between the patient and clinician.
That distinction matters. Personalized care is not about allowing an algorithm to decide what happens to you. It is about giving you and your clinician better information for a decision you make together.
What the Trial Found
The randomized controlled trial took place across 47 sites in Brazil, the United Kingdom, and Canada. A total of 540 participants were randomized, with 493 people diagnosed with major depressive disorder included in the primary analysis.
At eight weeks, the results suggested an important short-term benefit:
41 people in the PETRUSHKA group discontinued their antidepressant
69 people in the usual-care group discontinued treatment
That meant participants whose medication was selected with PETRUSHKA were approximately 40% less likely to stop treatment during the first eight weeks. They were also less likely to discontinue because of a side effect.
This does not mean that every person should remain on a medication no matter what. If a medication is unsafe, intolerable, or not helping, stopping or changing it may be the right decision, with guidance from a prescribing clinician. The value of the finding is that a better initial fit may help some people avoid giving up early because the treatment feels mismatched to their needs.
At 24 weeks, the difference in medication discontinuation was no longer clear. However, participants in the PETRUSHKA group reported better depression symptoms, anxiety symptoms, and quality of life.
The medications most often prescribed in the PETRUSHKA group were mirtazapine, escitalopram, and vortioxetine. In usual care, the most common medications were sertraline, citalopram, and fluoxetine. These results do not establish one group of medications as universally superior. They show how a different selection process may lead to different choices for different people.
Why Staying With Treatment Can Matter
Depression treatment is rarely a one-step process. Medication may take time to work. Side effects may appear before benefits do. A person may need dosage adjustments, a different medication, additional support, or a combination of approaches.
When treatment feels poorly matched, it can be difficult to continue long enough to evaluate whether it is helping. People may feel discouraged, misunderstood, or worried that nothing will work. A preference-sensitive approach can help make the process more transparent and collaborative from the beginning.
I often see this same principle in therapy. A client may benefit from structured cognitive behavioral therapy, while another may feel more comfortable beginning with mindfulness, narrative work, acceptance-based strategies, or supportive counseling. The approach needs to meet the person, not force the person into a predetermined format.
The most effective treatment is often not simply the one with the strongest results in a study. It is the one a person can access, understand, tolerate, and realistically stay engaged with.
The Trial Does Not Say That Medication Is the Whole Answer
There is an important limitation: the PETRUSHKA trial studied medication alone. It did not include psychotherapy as part of the treatment comparison.
The researchers noted that the same principle could apply to selecting therapy. This is a meaningful point because depression care does not need to be an either-or decision between medication and counseling.
For some people, medication can reduce symptoms enough to make daily life more manageable. Therapy can then help them understand patterns, process painful experiences, strengthen coping skills, improve relationships, and reconnect with their values. For others, therapy may be the preferred starting point. Some people benefit from both.
I view therapy as a partner to medication care, not a competitor. A trauma-informed, strengths-based counseling relationship can create a safe, supportive, and respectful space to explore what is happening and what kind of progress feels meaningful to you.
What the PETRUSHKA Results Do, and Do Not, Mean
The study is promising, but it should be interpreted thoughtfully.
The tool appeared to help more in primary care settings than in specialist psychiatric settings. That may suggest that structured decision support is especially useful where clinicians have less time or fewer specialized resources for detailed medication comparisons.
At the same time, participants and clinicians knew which treatment group they were in. This open-label design means that expectations, additional attention, or enthusiasm about the tool may have influenced some outcomes. There was also substantial missing data at 24 weeks, which makes the longer-term findings less certain.
PETRUSHKA is not a guarantee of remission, and it is not a replacement for clinical judgment. It is also not a reason to start, stop, or change an antidepressant without speaking with the clinician who prescribes it.
Instead, the trial supports a broader direction in mental health care: better decisions happen when professional expertise and personal knowledge are brought together.
How I Apply This Principle at Talk to Heal
At Talk to Heal Counseling Center, I begin by listening. I want to understand what you are experiencing, what has helped before, what has not felt right, and what you hope will change.
That conversation helps us consider an approach that fits your goals and circumstances. Depending on your needs, therapy may draw from evidence-based approaches such as:
Cognitive Behavioral Therapy
Acceptance and Commitment Therapy
Mindfulness-Based Cognitive Therapy
Narrative Therapy
Person-centered counseling
Positive Psychology
My goal is not to place you into a rigid category. It is to collaborate with you in a way that recognizes your strengths, respects your pace, and supports meaningful progress.
I also understand that access is part of fit. Talk to Heal offers free consultations, online booking, and insurance-friendly care. We accept UHC, Aetna, Cigna, and many other insurance providers. Therapy is available in multiple languages, including English and Korean, so you can seek support in a way that feels comfortable and accessible.
A Practical Conversation to Have With Your Prescribing Clinician
If you are considering an antidepressant or reviewing your current medication, you may want to ask your prescribing clinician:
What benefits are we hoping this medication will provide?
Which side effects should I watch for?
Which side effects are most important for me to avoid?
How might this medication fit with my sleep, work, relationships, or other health conditions?
How long should I try it before we evaluate whether it is helping?
What should I do if I feel worse or want to stop?
Could therapy, lifestyle changes, or additional support complement this treatment?
You are allowed to ask questions. You are allowed to share concerns. You are allowed to participate in the decision.
The Right Fit Is a Form of Respect
The PETRUSHKA trial does not tell us that one antidepressant is right for everyone. It reminds us that treatment should account for the whole person, not only a diagnosis or symptom score.
For me, that is the most hopeful part of this research. Depression care can become more personal, more collaborative, and more responsive to what people value. When clients feel heard and supported, they may be better positioned to engage with care and recognize their own capacity for growth.
If you are navigating depression, anxiety, medication questions, or a major life transition, you do not have to figure out the next step alone. I can help you explore therapy in a safe, supportive, and respectful setting. If medication is part of your care, therapy can work alongside that process while your prescribing clinician guides medication decisions.
Care is provided only in the State of Georgia.
Book a free consultation, book online, or call 404-369-3838 to get in touch.
Sources and Further Reading
Comments